Pharmaceutical company Collegium Pharmaceutical (NASDAQ: COLL) met Wall Street’s revenue expectations in Q3 2026, with sales up 3.3% year on year to $216.3 million. The company’s full-year revenue guidance of $840 million at the midpoint came in 0.8% above analysts’ estimates. Its non-GAAP profit of $1.96 per share was 5.6% above analysts’ consensus estimates.
Is now the time to buy COLL? Find out in our full research report (it’s free for active Edge members).
Collegium Pharmaceutical (COLL) Q3 2026 highlights:
- Revenue $216.3 million vs S&P analysts’ estimates of $216.8 million (3.3% year-on-year growth, in line)
- Adjusted EPS $1.96 vs S&P analysts’ estimates of $1.86 (5.6% beat)
- Adjusted EBITDA $121.6 million vs analyst estimates of $114.1 million (56.2% margin, 6.6% beat)
- Revenue guidance The company reconfirmed its revenue guidance for the full year of $840 million at the midpoint
- EBITDA guidance $457.5 million at the midpoint for the full year, above analyst estimates of $447.9 million
- Operating margin 13.3%, down from 29.7% in the same quarter last year
- Market capitalization $819.1 million
StockStory’s take
Collegium Pharmaceutical’s latest quarter was shaped by continued momentum in its ADHD portfolio, with strong growth in JORNAY PM and the first full-quarter contribution from AZSTARYS. Management attributed the positive performance to expanded commercial efforts, including increased sales force capacity and targeted promotional activities during the back-to-school season. CEO Vikram Karnani commented that, “JORNAY PM prescriptions grew by 16%, generating a record $51.9 million in net revenue.” The pain portfolio, while facing competitive and payer pressures, continued to provide steady cash flows that support investment in ADHD and strategic initiatives.
Looking forward, management’s reaffirmed guidance reflects confidence in further acceleration of its ADHD franchise and a deliberate strategy to maximize the value of its pain products. Karnani emphasized the company’s focus on growing both JORNAY PM and AZSTARYS, highlighting ongoing investments in commercial platforms and marketing as key to sustaining prescription growth. CFO Colleen Tupper noted plans to improve AZSTARYS gross-to-net profitability and continued evaluation of business development opportunities. Management also flagged the durable contribution of the pain portfolio, despite anticipated generic competition, as a source of support for ongoing R&D and capital returns.
Key insights from management’s remarks
Management attributed the quarter’s performance primarily to prescription growth in ADHD, the integration of AZSTARYS, and a resilient pain franchise providing cash flow for investment.
- ADHD franchise momentum: The company’s ADHD medicines, JORNAY PM and AZSTARYS, together accounted for over one-third of total revenue, with JORNAY PM delivering notable year-over-year prescription and new prescriber growth during the back-to-school period. Management credited expanded commercial infrastructure and targeted marketing for these gains.
- AZSTARYS integration and early traction: Having acquired AZSTARYS earlier this year, Collegium quickly integrated the product into its ADHD sales platform. This effort reversed the prior year’s prescription decline, with management citing physician awareness and dual-product promotion as catalysts for growth.
- Pain portfolio resilience: While legacy pain products like BELBUCA and XTAMPZA faced payer and generic pressures, management highlighted stable prescription volumes and upcoming formulary wins as evidence of the segment’s ongoing contribution to cash flow. BELBUCA revenue was flat sequentially, and XTAMPZA was set for expanded formulary access in the following year.
- Capital allocation priorities: Collegium continued to execute its strategy of investing in ADHD, pursuing business development, repaying debt, and returning capital to shareholders. A $50 million accelerated share repurchase program was initiated and is expected to be completed by year-end.
- Commercial platform expansion: The ADHD sales force grew to 190 representatives, enabling outreach to a broader healthcare provider base. Management also launched digital and awareness campaigns targeting both physicians and caregivers, aiming to further increase adoption of both ADHD medicines.
Drivers of future performance
Collegium expects further ADHD growth, stable pain portfolio cash flows, and commercial execution to shape performance in the coming quarters.
- ADHD growth initiatives: Management highlighted continued investments in sales force expansion, physician education, and direct-to-patient campaigns as central to accelerating prescription growth for JORNAY PM and AZSTARYS. The company believes enhanced awareness and differentiated product profiles will drive share gains in a market dominated by generics.
- Pain business headwinds and opportunities: The pain portfolio is expected to face ongoing generic and payer pressures, particularly for NUCYNTA, but management sees BELBUCA and XTAMPZA as stable cash generators. Key upcoming formulary wins and stable authorized generic pricing are expected to help offset some declines.
- Capital deployment flexibility: Management reiterated its approach of balancing business development, debt reduction, and share repurchases. The strong cash flow from the pain segment underpins this flexibility, while the company remains attentive to potential risks from generic entries and evolving market access dynamics.
Catalysts in upcoming quarters
In upcoming quarters, the StockStory team will watch (1) sustained prescription and prescriber growth for JORNAY PM and AZSTARYS following back-to-school seasonality, (2) progress in expanding formulary access for pain products such as XTAMPZA, and (3) any developments around generic competition for BELBUCA and NUCYNTA. Continued commercial execution and capital allocation decisions will also be important markers of success.
Collegium Pharmaceutical currently trades at $25.28, up from $23.67 just before the earnings. Is there an opportunity in the stock? See for yourself in our full research report (it’s free).
Our favorite stocks right now
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
